Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2001

View Archived Issues

Potent, selective and orally bioavailable CCR5 antagonist obtained at Schering-Plough

Additional patient enrollment suspended in phase III study of Aptosyn and Taxotere

Safer NSAIDs designed by linking ibuprofen to furoxan moieties

Genentech and Xoma to include additional study in Xanelim BLA submission to FDA

Folate-based thymidylate synthase inhibitor CW-252053 safe and effective in tumor-bearing mice

NeoPharm initiates phase I/II clinical trial for LEM in cancer

Positive results shown in preliminary analysis of phase II PTI-555 trial

Experimental dog model of osteoarthritis used to evaluate therapeutic effects of ML-3000

AtheroGenics reacquires rights to AGI-1067 from Schering-Plough

Pfizer's voriconazole recommended for treatment of acute invasive aspergillosis

Chondrocyte damage induced by proinflammatory cytokine attenuated by PBN

Nastech initiates phase I clinical trial of intranasal somatropin

Etoricoxib improves quality-of-life measures in osteoarthritis patients

PhotoCure begins phase III Hexvix program for bladder cancer detection

Airways effects of Y-27632 and procaterol compared in guinea pigs

Enrollment in phase II LDP-341 multiple myeloma trial completed ahead of schedule

Recombinant molecule selected for clinical development as mucositis therapy by Alizyme

L-Arginine has beneficial effects on blood pressure and erectile dysfunction in rat model

Agonists at PPAR receptors described by Merck for Rx of diabetes, etc.

Inhibitors of MMP and/or TNF-alpha reported in patent by Fujisawa

Fujisawa reveals new antiplatelet agents

Synthesis and use of nAChR receptor ligands described by AstraZeneca

Aniline thyroid hormone receptor agonists presented by BMS team

New pyrimidine compounds and use as chemokine receptor modulators